Latvian researchers have found five active chemical compounds that may serve as the base for the development of SARS-CoV-2 medicine in the future. However, currently the properties of these compounds do not yet meet the standards of medicines normally submitted for clinical trials.
In summer 2020 a total of ten projects were outlined in the state research programme to reduce Covid-19 consequences. One of those projects was Development of new therapeutic and prophylactic products against Covid-19 and coronaviruses performed by Latvian Biomedical Research and Study Centre in cooperation with Latvian Institute of Organic Synthesis, our Institute of Solid State Physics and Riga Technical University.
Part of this project is devoted towards development of new therapeutic products. To achieve this result, researchers search for substances that would be strong enough to kill the virus specifically. During the project researchers went through seven million commercially available compounds. Researchers then picked the ones with the highest potential.
